Wedbush Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Strong-Buy

Wedbush upgraded shares of Avalo Therapeutics (NASDAQ:AVTX) to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.

Other analysts have also recently issued research reports about the company. BTIG Research assumed coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price objective for the company. HC Wainwright assumed coverage on Avalo Therapeutics in a research report on Thursday, October 24th. They issued a “neutral” rating for the company.

Avalo Therapeutics Trading Up 17.9 %

Shares of NASDAQ:AVTX opened at $8.44 on Thursday. Avalo Therapeutics has a 12-month low of $4.20 and a 12-month high of $34.46. The business’s fifty day simple moving average is $7.82 and its 200-day simple moving average is $9.40.

Institutional Trading of Avalo Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Velan Capital Investment Management LP acquired a new stake in Avalo Therapeutics during the 4th quarter worth about $817,000. BVF Inc. IL boosted its holdings in shares of Avalo Therapeutics by 7.2% during the 4th quarter. BVF Inc. IL now owns 1,036,679 shares of the company’s stock worth $7,703,000 after purchasing an additional 69,679 shares during the last quarter. Allostery Investments LP acquired a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $545,000. Northern Trust Corp acquired a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $168,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after purchasing an additional 3,754 shares during the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.